Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572175 · ClinicalTrials.gov registry record · Phase 2
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Not yet
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07572175 is a Phase 2 study that has not yet begun recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 60 participants.
The verdict
NCT07572175, a Phase 2 study, has not yet begun recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Interventions
- DRUG Placebo
- DRUG Sotagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07572175
The ClinicalTrials.gov registry entry for NCT07572175 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07572175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07572175 about?
NCT07572175 is a clinical study titled "Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity". This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
What is the current status of trial NCT07572175?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-07. Estimated completion is 2029-10.
What interventions are being tested in trial NCT07572175?
The interventions under investigation include: Placebo (DRUG), Sotagliflozin (DRUG).
Who is sponsoring clinical trial NCT07572175?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.